India Caps Trade Margins at 30% on 137 Anti-Cancer Drugs, Prices to Fall
India's National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs, effective November 9, 2026. This measure aims to reduce retail prices by up to 70%, improving affordability and access to cancer treatments. The list, recommended by an expert committee under the Directorate General of Health Services, includes widely used immunotherapies and targeted therapies. Manufacturers must revise prices accordingly, and compliance will be monitored by state drug controllers and hospitals. The list will be updated periodically.
First-hand measurement across 14 sources
We measured how 14 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 57/100.
Outlets measured: economictimes, hindustantimes, indianexpress, theprint, mint, thehindu, indiatoday, thestatesman, and 6 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment ranged widely across outlets — from 32/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
economictimes broke this story on 17 Oct, 02:29 pm. Other outlets followed.